Jazz Pharmaceuticals (JAZZ)

In neuroscience, Jazz is best known for its narcolepsy franchise. Xyrem and Xywav are used to treat symptoms associated with narcolepsy, including excessive daytime sleepiness and cataplexy, while Xywav also reflects the company’s effort to maintain leadership in oxybate-based therapy with a lower-sodium formulation. The acquisition of GW Pharmaceuticals in 2021 expanded Jazz into cannabinoid-based prescription medicines through Epidiolex, a treatment for seizures associated with severe, rare forms of epilepsy.

Jazz’s oncology business includes products such as Zepzelca for metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukaemia and lymphoblastic lymphoma in certain settings, and Vyxeos for acute myeloid leukaemia. These medicines target areas where treatment options can be limited and where specialist commercial infrastructure is important.

The company’s investment case is shaped by its ability to defend and grow established products, broaden the use of newer therapies, advance its clinical pipeline, and manage patent, regulatory, and reimbursement risks. Jazz operates in competitive markets where clinical differentiation and payer access are central, but its emphasis on complex, specialist conditions gives it a distinct position within the biopharmaceutical sector.